Decoy Therapeutics seeks stockholder approval for up to 2.96 million warrant shares and a reduction in authorized shares

summarizeSummary

Decoy Therapeutics filed a preliminary proxy for a September 14 special meeting to approve the exercise of 2.96 million Milestone Warrants from its June private placement, potentially raising $17.5 million but causing massive dilution, and to reduce authorized shares by 10 million.

check_boxKey Events · Financing and Capital Events · DCOY

• Warrant Exercise Vote Sought

  Stockholders will vote on allowing the exercise of 2,961,085 Milestone Warrants issued in the June 29 private placement. If approved and exercised for cash, the company could receive up to $17.5 million in additional proceeds.

• Massive Potential Dilution

  The 2.96 million warrant shares represent over 500% of the 590,185 shares currently outstanding. Full exercise would severely dilute existing holders, though the warrants are tied to clinical milestones and expire if milestones aren't met.

• Clinical Milestones Tied to Warrants

  Each series of warrants expires 90 days after a specific clinical milestone: Series A upon filing a Clinical Trial Application in the EEA; Series B upon MHRA approval for a Phase 2a human challenge trial; Series C upon announcement that the Phase 2a trial met its primary endpoint.

• Authorized Share Reduction Proposed

  The board proposes reducing authorized common shares from 100 million to 90 million, a move that may limit future dilution but could constrain financing flexibility if the company needs to raise additional capital.

auto_awesomeAnalysis · DCOY · Life Sciences

Decoy Therapeutics is asking stockholders to approve the exercise of 2.96 million Milestone Warrants issued in its June 29 private placement. If approved and all warrants are exercised for cash, the company could raise up to $17.5 million in additional proceeds — critical funding for a clinical-stage biotech with a going concern warning and a cash runway only into late 2026. However, the warrants represent potential dilution of over 500% relative to the 590,185 shares currently outstanding. The proxy also proposes reducing authorized shares from 100 million to 90 million, a governance move that may signal the board's intent to limit future dilution but could constrain financing flexibility. The filing reveals for the first time the specific clinical milestones that trigger warrant expiration, tying the financing to the company's pipeline progress.